Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures
<p>Abstract</p> <p>I believe that the FDA guidelines have already had an impact in encouraging good practice in the use of PROs. There are, however, important improvements that need to be made to the guidelines, particularly in the use of health status and quality of life terminolo...
Main Author: | Bradley Clare |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-10-01
|
Series: | Health and Quality of Life Outcomes |
Online Access: | http://www.hqlo.com/content/4/1/78 |
Similar Items
-
FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
by: Elizabeth S. Russell, et al.
Published: (2023-01-01) -
Patient reported outcome measures (PRO) in colorectal surgery
by: Kathia E. Nitsch, BS, et al.
Published: (2024-06-01) -
Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
by: John E. Harrison
Published: (2018-06-01) -
EPRO MIGRATION AND USABILITY TESTING OF PATIENT-REPORTED OUTCOME (PRO) MEASURES
by: Wilkins, G, et al.
Published: (2013) -
Patient reported outcome (PRO) measurement of disability in orthopaedic trauma to the upper extremity
by: Jayakumar, P
Published: (2017)